Audiological and Quality of Life Outcomes of Anatomy Based Fitting in Patients Implanted by Robot Assisted Cochlear Implant Surgery (RACIS)
Launched by UNIVERSITAIR ZIEKENHUIS BRUSSEL · May 5, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a new way of programming cochlear implants (CIs) can improve hearing outcomes and quality of life for people with severe to profound hearing loss. Right now, many CIs are set using a standard approach that doesn’t consider the individual shapes and sizes of patients' inner ears. This study will use special imaging from CT scans to create a more personalized fitting plan that aims to match natural hearing patterns better. Participants will be patients who have already received a cochlear implant through a robotic surgery system and are using specific types of MED-EL implants.
To be eligible for this trial, participants must be at least 18 years old and have severe to profound hearing loss in one or both ears. They need to be implanted with a MED-EL cochlear implant and are set to receive a specific audio processor. Additionally, they should have had pre-operative hearing tests and scans available. Participants will undergo assessments to see how well this new fitting strategy works for them, and they can expect to be part of a study that may lead to better hearing solutions for others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Post-lingual onset of severe to profound sensory-neural hearing loss in the implanted ear(s)
- • Subject implanted by Robot Assisted Cochlear Implant Surgery (RACIS)
- • Subject implanted with MED-EL cochlear implant(s) with Flex28, Flex 26 or FlexSoft electrode to obtain maximum cochlear coverage
- • Subject planned to receive a MED-EL SONNET 2 or RONDO 3 audio processor on the newly implanted side
- • Subject is either a user with unilateral implantation, bilateral implantation or a bimodal CI user (unilateral CI user with contralateral ear adequately fitted with a hearing aid)
- • Pre- operative and post-operative CT scan of the temporal bone available
- • Pre-operative result of pure-tone audiometry, speech test in quiet and in noise available
- • Audio processor not yet activated on the newly implanted side
- • Minimum of 10 active channels can be activated
- • Fluent in the language of the test centre (Dutch or French)
- • Signed and dated ICF before the start of any study-specific procedure
- Exclusion Criteria:
- • Subject is a Single-Sided Deafness (SSD) CI user
- • Subject is an Electric Acoustic Stimulation (EAS) user (with an EAS audio processor)
- • Lack of compliance with any inclusion criteria
- • Anything that, in the opinion of the Investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study
About Universitair Ziekenhuis Brussel
Universitair Ziekenhuis Brussel (UZ Brussel) is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent institution affiliated with the Vrije Universiteit Brussel, UZ Brussel integrates cutting-edge medical research with high-quality patient care. The hospital's multidisciplinary teams are dedicated to exploring novel therapeutic approaches and contributing to the development of evidence-based treatments, ensuring the highest standards of safety and efficacy in clinical research. With a strong focus on collaboration and knowledge dissemination, UZ Brussel plays a pivotal role in shaping the future of medicine and improving patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussel, , Belgium
Patients applied
Trial Officials
Vedat Topsakal, Prof.
Principal Investigator
UZB-VUB
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials